Clinical trials: Lung Cancer
Breast Cancer, Ovarian Cancer
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors
- Conditions
- Breast Cancer, Ovarian Cancer, Gynecological Cancer, Head and Neck Carcinoma
- Trial name
- NCT01831089
- Testing
- PM01183 + paclitaxel +/- bevacizumab
- Where
- 3 sites in United States, Spain and 1 more
- Volunteers
- 69 people
- Sponsor
- PharmaMar
Breast Cancer, Endometrial Cancer
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
RATIONALE: Metformin and temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Breast Cancer, Endometrial Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00659568
- Testing
- metformin hydrochloride, temsirolimus
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- London Health Sciences Centre
Lung Cancer
Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00075374
- Testing
- docetaxel
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Case Comprehensive Cancer Center
Non-Small Cell Lung Cancer
A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients
This study is to evaluate the safety, tolerability, clinical efficacy and pharmacokinetics of continuous Endostar intravenous infusion combined with pemetrexed and carboplatin in advanced non small cell lung cancer (NSCLC)…
- Trial name
- NCT01531790
- Testing
- Carboplatin, Pemetrexed, Endostar
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Neurological Outcome, Survival From First Diagnosis Metastatic Spinal Cord Compression to Death
Emergency Radiotherapy in Metastatic Spinal Cord Compression of Patients With Non-small Cell Lung Cancer
Acute neurological deficit in metastatic spinal cord compression is an emergency condition in radiation oncology. Despite some reports about the high efficacy of radiation treatment for oncological emergencies, a standard of care…
- Trial name
- CK-INF (NCT02000518)
- Testing
- external beam radiotherapy
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Heidelberg University
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment…
- Trial name
- NCT02431260
- Testing
- INCB054329 Monotherapy
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Nonsmall Cell Lung Cancer
Chemotherapy With or Without Radiosurgery for Asymptomatic Oligo Brain Metastasis
The need of radiosurgery is controversial for asymptomatic oligo brain metastasis for non small cell lung cancer (NSCLC). Therefore, the investigators do a randomized study comparing overall survival between two groups with or…
- Trial name
- NCT01301560
- Testing
- Radiosurgery, Observation
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Samsung Medical Center
Breast Cancer, Biliary Tract Carcinoma
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
- Conditions
- Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT05123482
- Testing
- AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib)
- Where
- 67 sites in United States, Australia and 13 more
- Volunteers
- 460 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Study to determine the maximum tolerated dose (MTD) and safety profile of a single-dose administration of sibrotuzumab (50 mg) conjugated to an increasing dose of 131 I isotope.
- Trial name
- NCT02209727
- Testing
- 131I-Sibrotuzumab
- Volunteers
- 9 people
- Sponsor
- Boehringer Ingelheim
Covid19, Prostate Specific Antigen
Changing of Prostate Specific Antigen Value in Patients With Covid-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a worldwide pandemic in over 100 years. The disease caused by this newly discovered virus was called Covid-19.
- Trial name
- NCT05009186
- Testing
- PSA value
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Saglik Bilimleri Universitesi
Non-small-Cell Lung Carcinoma, Surgery
N2 Lung Cancer Project: Neoadjuvant Treatment Followed Surgery Versus Chemoradiation
The objective of this multicenter retrospective study is to compare overall survival in patients with stage IIIA-N2 NSCLC treated with neoadjuvant treatment and surgery versus definitive chemoradiation.
- Conditions
- Non-small-Cell Lung Carcinoma, Surgery, Stage IIIA-N2, Chemoradiation
- Trial name
- NCT02966769
- Testing
- Overall survival
- Where
- Spain
- Volunteers
- 294 people
- Sponsor
- Grupo de Investigación Clínica en Oncología Radioterapia
Non-Small Cell Lung Cancer
Saliva mRNA Expression Profiling for Early Stage Non-Small Cell Lung Cancer Screening
This is a pilot study to test the feasibility of using gene expression from saliva to identify patients with early-stage non-small cell lung cancer (NSCLC).
- Trial name
- SPIT-LC (NCT00607425)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Scottsdale Healthcare
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer
This phase Ib/II trial studies the side effects and best dose of aurora A kinase inhibitor LY3295668 when given together with osimertinib in patients with EGFR-mutant non-squamous non-small cell lung cancer that has spread to…
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT05017025
- Testing
- Aurora A Kinase Inhibitor LY3295668, Osimertinib
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer
This is an open-label, single-arm, Phase I/II trial to determine the safety of RAD001 in combination with docetaxel and compare the efficacy of RAD001 plus docetaxel versus published Phase II and III reports of docetaxel alone in…
- Trial name
- NCT00406276
- Testing
- RAD001, Docetaxel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Emory University
Small Cell Lung Cancer
NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer.
Natural killer (NK) cells can kill a broad array of tumor cells in a non-major histocompatibility complex(MHC)-restricted manner. Adoptive transfer of NK may prolong the survival of patients with cancer.
- Trial name
- NCT03410368
- Testing
- NK cells
- Where
- China
- Volunteers
- 120 people
- Sponsor
- jiuwei cui
Metastatic NSCLC, Metastatic Head and Neck Cancer
Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers
Immunotherapy is widely administrated as anticancer treatment in metastatic setting. Despite a proved efficacy in several cancer types and clinical situations, it exists a wide variability of responses in terms of efficacy and…
- Trial name
- MADMAS (NCT05091190)
- Testing
- Blood draws
- Where
- 2 sites in France
- Volunteers
- 75 people
- Sponsor
- Hospices Civils de Lyon
Breast Cancer, Lung Cancer
Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel
Explore the randomized, controlled, double-blind design targeted for the final clinical trial to assess the acceptability of interventions and clinical outcome measures and to provide data making it possible to estimate the…
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer, Oesophageal Cancer
- Trial name
- PREMED-F1 (NCT04237090)
- Testing
- Diphenhydramine, Cetirizine, Lactose pill
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Smoking Cessation
Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites
This study is to help determine the most effective type or combination of treatments to offer patients seeking lung cancer screening who are smokers to help them reduce the number of cigarettes they smoke, or quit smoking.
- Trial name
- NCT03315910
- Testing
- Motivational Interviewing (MI), Nicotine Replacement Therapy (NRT), Nicotine Lozenge
- Where
- 18 sites in United States
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma
Q702 for the Treatment of Patients With Hematologic Malignancies
This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents.
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT06712810
- Testing
- Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Mayo Clinic
Colorectal Neoplasms Malignant
Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
Colorectal cancer (CRC) is the third most common cancer worldwide. Surgical resection is one of the primary treatment options for CRC; however, postoperative recurrence remains a significant clinical challenge for both the…
- Trial name
- NCT06778382
- Testing
- Oligometastasis Treatment
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shandong Cancer Hospital and Institute